In a challenging year for biotechnology firms, PureTech Health PLC (PRTC) stock has touched a 52-week low, dipping to $16.81.

PureTech also has discovery and preclinical-stage candidates in oncology, including anti-Galectin-9 and Delta-1 antibodies for solid tumours. Image by Gerd Altmann from Pixabay Image ...

PureTech has presented data demonstrating high expression of galectin-9 across various solid tumor types and blood cancers and has found that, in several cancers, galectin-9 levels correlate with ...

PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class ...

PureTech expects to announce topline results in mid-2021. This follows a phase 1 trial of the drug in March testing its safety, tolerabili ty and pharmacokinetic profile in several doses in ...

LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

Check the time stamp on this data. Updated AI-Generated Signals for Puretech Health Plc (PRTC) available here: PRTC. Type a ...

PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment ...

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

GET MORE AI-GENERATED SIGNALS: January 10, 2025, 20:42 pm ET, BY Rick W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...

(RTTNews) - Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LYT-200, a first-in-class ...